Fritextsökning
Artiklar per år
Innehållstyper
-
New partnering platform
EBD Group's Partnering One is the new partnering platform for Biotech Forum 2009.
-
Multilabel plate readers with luminescence capability
The Enspire Multilabel Plate Reader platform from Perkin Elmer now features sensitive luminescence detection. The new detection capability is primarily aimed at improving assay performance and sensitivity for scientists working with primary cells or stem cells in cancer and neuropharmacology research.
-
The winner of the race
She learned how to work hard at an early age and her devotion has certainly paid off. Whether it is field running or running a company, the key to success is focus according to Yvonne Mårtensson.
-
En affärsmodell på väg att dö
"Let us be lovers, we'll marry our fortunes together. I've got some real estate here in my bag", Det luspanka unga bussluffarparet i Simon & Garfunkels "America" lovar varandra dyrt och heligt vad som idag är i princip ingenting, men som man hoppas ska
-
Raka spåret in i USA
Euris sluter avtal med det amerikanska bolaget Ocean Nano Tech, som ska distribuera bolagets produkter på den amerikanska marknaden.
-
Swedish nanotech crosses the Atlantic
Genovis signs distribution agreement Finnzymes in US.
-
Trio goes in for high tech medicines
The Swedish drug discovery company Beactica announces fragment-based drug discovery research collaboration with GE Healthcare and the University of Uppsala.
-
Collaboration brings next generation drugs
Wyeth and Santaris Pharma announce a new alliance to develop RNA-based medicines.
-
A platform for dialogue
As a step towards connecting the life science industry in Denmark, Biologue was founded three years ago with 10 member companies. Today, the network has 40 members and a very busy event calender.
-
Bring talent to those in need
Ho ho ho, Christmas time is here again. So get busy decking the halls, perhaps not with assorted greenery, but with something of a more lasting value.
-
Time to save for survival
The future is bright for the biotech industry. However, the companies need to cut costs immediately if they want to survive the rough economic times.
BREAKING